Cardiotoxicity (CDTX) is a critical side effect of many cancer therapies, leading to increased
morbidity and mortality if not addressed. Early detection of CDTX is essential, and while …

Although anthracyclines are important anticancer agents, their use is limited due to various
adverse effects, particularly cardiac toxicity. Mechanisms underlying anthracycline-induced …

Background: Anthracycline cardiotoxicity is a well-known complication of cancer treatment,
and miRNAs have emerged as a key driver in the pathogenesis of cardiovascular diseases …

Breast cancer (BC) is the most frequent type of female cancer with increasing incidence in
recent years. Doxorubicin (DOX) is an important backbone chemotherapy in BC, responsible …

Opinion Statement Anthracycline (ANT)-induced cardiotoxicity (AIC) is a particularly
prominent form of cancer therapy-related cardiovascular toxicity leading to the limitations of …

Close monitoring for cardiotoxicity during anthracycline chemotherapy is crucial for early
diagnosis and therapy guidance. Currently, monitoring relies on cardiac imaging and serial …

The present study aimed to investigate the effects of microRNA (miR)‑96 on the proliferation
and migration of breast cancer cells, and indicated that miR‑96 may have a promoting role in …

Cancer survivors are at a much greater risk of developing cardiovascular diseases due to
cardiotoxic chemotherapy. Anthracyclines, antimetabolites and alkylating agents are known …

Anthracyclines are widely used in the treatment of clinical tumors, but their cardiotoxicity has
become a significant factor limiting their use. Cardiotoxicity can lead to severe myocardial …

Aim this study aims to evaluate the response of muscle-specific (miR-1, miR-133, miR-208,
miR-486, miR-499) and inflammation-related (miR-21, miR-146, and miR-155) miRNAs, well …